Rep. Kelly Morrison Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Representative Kelly Morrison sold shares of Johnson & Johnson (NYSE:JNJ) worth between $1,001 and $15,000 on August 19th, 2025.
• Johnson & Johnson reported quarterly earnings of $2.77 per share, which beat estimates, with revenues reaching $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, yielding approximately 2.9%, with a dividend payout ratio of 55.61%.

Representative Kelly Morrison (D-Minnesota) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 19th. The trade occurred in the Representative's "TRUST 2" account.

Representative Kelly Morrison also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Verizon Communications NYSE: VZ on 8/19/2025.
• Sold $15,001 - $50,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $15,001 - $50,000 in shares of Thermo Fisher Scientific NYSE: TMO on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 8/19/2025.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.40 on Friday, hitting $178.10. The company had a trading volume of 7,220,047 shares, compared to its average volume of 7,548,205. The business has a 50-day simple moving average of $170.81 and a 200-day simple moving average of $161.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $428.93 billion, a PE ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently made changes to their positions in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $4,877,174,000. Nuveen LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $1,369,188,000. Laurel Wealth Advisors LLC lifted its position in Johnson & Johnson by 15,040.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company's stock worth $1,133,512,000 after buying an additional 7,371,687 shares in the last quarter. GAMMA Investing LLC lifted its position in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on JNJ shares. Guggenheim reiterated a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Citigroup increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $176.29.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

About Representative Morrison

Kelly Morrison (Democratic Party) is a member of the U.S. House, representing Minnesota's 3rd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Morrison (Democratic Party) is running for re-election to the U.S. House to represent Minnesota's 3rd Congressional District. She declared candidacy for the 2026 election. Kelly Morrison was born in Minneapolis, Minnesota, and lives in Deephaven. Morrison earned a B.A. in history from Yale University and an M.D. from Case Western Reserve University. She completed her residency in obstetrics and gynecology at Northwestern University. Morrison's career experience includes working as a physician.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.